BACKGROUND/AIMS: NG2 is the rat homologue of the human melanoma proteoglycan (HMP), also known as the high molecular weight melanoma associated antigen. Most cutaneous melanomas, as well as glioblastomas, chondrosarcomas, and some leukaemias express NG2 immunoreactivity, recognised using monoclonal antibody (mAb) 9.2.27. This antibody has also been used for molecular targeting in targeted alpha therapy for melanoma. The purpose of this study was to evaluate the expression of NG2 immunoreactivity in human uveal melanoma and normal ocular tissue using mAb 9.2.27. METHODS: Enucleated eyes from 26 patients with choroidal or ciliary body melanoma (n=26) were available as paraffin sections, and stained with haematoxylin and eosin to assess for tumour cell type and histopathology. Additional slides were investigated for NG2 immunoreactivity using mAb 9.2.27 and alkaline phosphatase anti-alkaline phosphatase (APAAP) immunostaining. Two independent observers graded immunostaining using a semiquantitative scale from 0 (negative) to 3 (strong). RESULTS: Immunostaining for mAb 9.2.27 could not be graded in 7/26 cases with dense pigmentation of the tumour. For the remaining cases, grade 2 (moderate) or more immunostaining was seen in 18/19 tumours (95%). The retina, retinal pigment epithelium (RPE), and choroid displayed weak immunostaining (grade 0.5-1.5) in the majority of melanoma affected eyes. Normal retina and choroid (n=5) appeared negative for mAb 9.2.27. Optic nerve axon bundles in both control and melanoma affected eyes displayed moderate immunostaining. CONCLUSION: In the present study, the majority of human uveal melanomas expressed NG2 immunoreactivity, as detected using mAb 9.2.27. This antibody may be a suitable candidate for radioimmunotherapy to target ocular melanoma.
BACKGROUND/AIMS: NG2 is the rat homologue of the humanmelanoma proteoglycan (HMP), also known as the high molecular weight melanoma associated antigen. Most cutaneous melanomas, as well as glioblastomas, chondrosarcomas, and some leukaemias express NG2 immunoreactivity, recognised using monoclonal antibody (mAb) 9.2.27. This antibody has also been used for molecular targeting in targeted alpha therapy for melanoma. The purpose of this study was to evaluate the expression of NG2 immunoreactivity in humanuveal melanoma and normal ocular tissue using mAb 9.2.27. METHODS: Enucleated eyes from 26 patients with choroidal or ciliary body melanoma (n=26) were available as paraffin sections, and stained with haematoxylin and eosin to assess for tumour cell type and histopathology. Additional slides were investigated for NG2 immunoreactivity using mAb 9.2.27 and alkaline phosphatase anti-alkaline phosphatase (APAAP) immunostaining. Two independent observers graded immunostaining using a semiquantitative scale from 0 (negative) to 3 (strong). RESULTS: Immunostaining for mAb 9.2.27 could not be graded in 7/26 cases with dense pigmentation of the tumour. For the remaining cases, grade 2 (moderate) or more immunostaining was seen in 18/19 tumours (95%). The retina, retinal pigment epithelium (RPE), and choroid displayed weak immunostaining (grade 0.5-1.5) in the majority of melanoma affected eyes. Normal retina and choroid (n=5) appeared negative for mAb 9.2.27. Optic nerve axon bundles in both control and melanoma affected eyes displayed moderate immunostaining. CONCLUSION: In the present study, the majority of humanuveal melanomas expressed NG2 immunoreactivity, as detected using mAb 9.2.27. This antibody may be a suitable candidate for radioimmunotherapy to target ocular melanoma.
Authors: G Pluschke; M Vanek; A Evans; T Dittmar; P Schmid; P Itin; E J Filardo; R A Reisfeld Journal: Proc Natl Acad Sci U S A Date: 1996-09-03 Impact factor: 11.205
Authors: M Chekenya; C Krakstad; A Svendsen; I A Netland; V Staalesen; B B Tysnes; F Selheim; J Wang; P Ø Sakariassen; T Sandal; P E Lønning; T Flatmark; P Ø Enger; R Bjerkvig; M Sioud; W B Stallcup Journal: Oncogene Date: 2008-05-12 Impact factor: 9.867
Authors: Agnete Svendsen; Joost J C Verhoeff; Heike Immervoll; Jan C Brøgger; Justyna Kmiecik; Aurelie Poli; Inger A Netland; Lars Prestegarden; Jesús Planagumà; Anja Torsvik; Anneli Bohne Kjersem; Per Ø Sakariassen; Jan I Heggdal; Wouter R Van Furth; Rolf Bjerkvig; Morten Lund-Johansen; Per Ø Enger; Joerg Felsberg; Nicolaas H C Brons; Karl J Tronstad; Andreas Waha; Martha Chekenya Journal: Acta Neuropathol Date: 2011-08-24 Impact factor: 17.088
Authors: Aaron B Beasley; Timothy W Isaacs; Tersia Vermeulen; James Freeman; Jean-Louis DeSousa; Riyaz Bhikoo; Doireann Hennessy; Anna Reid; Fred K Chen; Jacqueline Bentel; Daniel McKay; R Max Conway; Michelle R Pereira; Bob Mirzai; Leslie Calapre; Wendy N Erber; Melanie R Ziman; Elin S Gray Journal: Cancers (Basel) Date: 2021-11-28 Impact factor: 6.639